Cargando…

The impact of angiogenesis inhibitors on survival of patients with small cell lung cancer

BACKGROUND: Small cell lung cancer (SCLC) is a highly invasive and lethal neuroendocrine tumor. Antiangiogenic drugs have been reported in the treatment of SCLC. We aimed to provide a comprehensive evaluation of the impact of angiogenic inhibitors on SCLC survival using network meta‐analysis. METHOD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Xiaoshun, Dong, Xiaoying, Young, Sylvia, Chen, Allen Menglin, Liu, Xiguang, Zheng, Zhouxia, Huang, Kailing, Lu, Di, Feng, Siyang, Morahan, Grant, Cai, Kaican
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792507/ https://www.ncbi.nlm.nih.gov/pubmed/31433125 http://dx.doi.org/10.1002/cam4.2462

Ejemplares similares

The first comprehensive database of germline pathogenic variants in East Asian cancer patients
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma
por: Lu, Di, et al.
Publicado: (2020)

IRGS: an immune-related gene classifier for lung adenocarcinoma prognosis
por: Shi, Xiaoshun, et al.
Publicado: (2020)

Differential effects of adjuvant EGFR tyrosine kinase inhibitors in patients with different stages of non-small-cell lung cancer after radical resection: an updated meta-analysis
por: Lu, Di, et al.
Publicado: (2019)

Cancer susceptibility genes: update and systematic perspectives
por: Shi, Xiaoshun, et al.
Publicado: (2022)

Survival-related risk score of lung adenocarcinoma identified by weight gene co-expression network analysis
por: Wang, He, et al.
Publicado: (2019)

Current Evidence of the Efficacy and Safety of Neoadjuvant EGFR-TKIs for Patients With Non-small Cell Lung Cancer
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Authors' response: Comment on “clinicopathological features, survival outcomes, and appropriate surgical approaches for stage I acinar and papillary predominant lung adenocarcinoma”
por: Lu, Di, et al.
Publicado: (2022)

Trends, Symptoms, and Outcomes of Resectable Giant Mediastinal Tumors
por: Shi, Xiaoshun, et al.
Publicado: (2022)

Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages
por: Lu, Di, et al.
Publicado: (2019)

Identification of Genetic Variants Associated with Sex-Specific Lung-Cancer Risk
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation
por: Kodama, Hiroaki, et al.
Publicado: (2021)

Machine Learning Models to Predict Primary Sites of Metastatic Cervical Carcinoma From Unknown Primary
por: Lu, Di, et al.
Publicado: (2020)

Novel PHOX2B germline mutation in childhood medulloblastoma: a case report
por: Ke, Caiping, et al.
Publicado: (2021)

Circular RNA circNELL2 Acts as the Sponge of miR-127-5p to Promote Esophageal Squamous Cell Carcinoma Progression
por: Xiong, Gang, et al.
Publicado: (2020)

The Current Situation of Esophageal Cancer Staging and Perioperative Strategies Determination in Central and Southern China: A Cross Sectional Survey
por: Lu, Di, et al.
Publicado: (2019)

Lung segmentectomy assisted by highly selective independent segmental ventilation: a series of three cases
por: Shi, Xiaoshun, et al.
Publicado: (2021)

Effects of HAR1 on cognitive function in mice and the regulatory network of HAR1 determined by RNA sequencing and applied bioinformatics analysis
por: Zhang, Luting, et al.
Publicado: (2023)

Cross-platform genomic identification and clinical validation of breast cancer diagnostic biomarkers
por: Liu, Dongdong, et al.
Publicado: (2021)

The power of tumor sizes in predicting the survival of solitary hepatocellular carcinoma patients
por: Yang, Anli, et al.
Publicado: (2018)

Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade
por: Yang, Jianjun, et al.
Publicado: (2020)

Efficacy and safety of anlotinib, a multikinase angiogenesis inhibitor, in combination with epirubicin in preclinical models of soft tissue sarcoma
por: Wang, Zhi‐Ming, et al.
Publicado: (2020)

Survival benefit from immunocheckpoint inhibitors in stage IV non‐small cell lung cancer patients with brain metastases: A National Cancer Database propensity‐matched analysis
por: Takamori, Shinkichi, et al.
Publicado: (2020)

Potential of Small Molecule Protein Tyrosine Kinase Inhibitors as Immunomodulators and Inhibitors of the Development of Diabetes
por: Little, Peter J., et al.
Publicado: (2009)

A new scoring system for predicting survival in patients with non-small cell lung cancer
por: Schild, Steven E, et al.
Publicado: (2015)

Stereotactic body radiotherapy improves the survival of patients with oligometastatic non‐small cell lung cancer
por: Ouyang, Wen, et al.
Publicado: (2019)

Effects of thoracic radiotherapy timing and duration on progression‐free survival in limited‐stage small cell lung cancer
por: Zhao, Shen, et al.
Publicado: (2018)

Socioeconomic disparity trends in diagnostic imaging, treatments, and survival for non‐small cell lung cancer 2007‐2016
por: Shah, Monica, et al.
Publicado: (2020)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy
por: Feng, Siyang, et al.
Publicado: (2015)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence
por: Byeon, Seonggyu, et al.
Publicado: (2020)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Impact of visceral pleural invasion on the association of extent of lymphadenectomy and survival in stage I non‐small cell lung cancer
por: Wo, Yang, et al.
Publicado: (2019)

Chemotherapy treatments, costs of care, and survival for patients diagnosed with small cell lung cancer: A SEER‐Medicare study
por: Shao, Changxia, et al.
Publicado: (2019)

Predictive value of pretreatment albumin‐to‐alkaline phosphatase ratio for overall survival for patients with advanced non‐small cell lung cancer
por: Zhou, Shaozhang, et al.
Publicado: (2020)

Predictive factors for progression‐free survival in non‐small cell lung cancer patients receiving nivolumab based on performance status
por: Adachi, Yuichi, et al.
Publicado: (2019)

Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib
por: Qin, Boyu, et al.
Publicado: (2021)

Different genetic mechanisms mediate spontaneous versus UVR-induced malignant melanoma
por: Ferguson, Blake, et al.
Publicado: (2019)

Copy‐number variation of MCL1 predicts overall survival of non‐small‐cell lung cancer in a Southern Chinese population
por: Yin, Jieyun, et al.
Publicado: (2016)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5mpo4589io5l8222ofhqf9a4fd